isomethyleugenol has been researched along with Lewy Body Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Francis, P; Geut, H; Hannon, E; Henriksen, SP; Love, S; Mill, J; Pihlstrøm, L; Rozemuller, AJM; Shireby, G; Thomas, AJ; Toft, M; Tunold, JA; van de Berg, WDJ | 1 |
| Iga, JI; Nagai, M; Nomoto, M; Ochi, S; Ozaki, Y; Ueno, SI; Yamazaki, K; Yoshino, Y | 1 |
| Ariza, A; Beyer, K; Domingo-Sàbat, M; Ferrer, I; Santos, C; Tolosa, E | 1 |
1 review(s) available for isomethyleugenol and Lewy Body Disease
| Article | Year |
|---|---|
Epigenome-wide association study of human frontal cortex identifies differential methylation in Lewy body pathology.
Topics: alpha-Synuclein; Epigenome; Frontal Lobe; Humans; Lewy Bodies; Lewy Body Disease; Methylation; Parkinson Disease | 2022 |
2 other study(ies) available for isomethyleugenol and Lewy Body Disease
| Article | Year |
|---|---|
DRD2 methylation to differentiate dementia with Lewy bodies from Parkinson's disease.
Topics: Aged; Aged, 80 and over; Biomarkers; Diagnosis, Differential; Female; Humans; Leukocytes; Lewy Body Disease; Male; Methylation; Parkinson Disease; Receptors, Dopamine D2 | 2020 |
The decrease of β-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies.
Topics: 5' Untranslated Regions; Aged; Aged, 80 and over; Alzheimer Disease; Amyloidosis; beta-Synuclein; Blotting, Western; Brain Chemistry; Caudate Nucleus; Cerebral Cortex; Female; Humans; Immunohistochemistry; Lewy Body Disease; Male; Methylation; Middle Aged; Neurofibrillary Tangles; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2010 |